Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07503782 · ClinicalTrials.gov registry record · Phase 2
OEA for Young Adults With Alcohol Use Disorder
A Phase 2 study, sponsored by Medical University of South Carolina.
- Not yet
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT07503782 is a Phase 2 study that has not yet begun recruiting, run by Medical University of South Carolina. The registered enrollment target is 42 participants.
The verdict
NCT07503782, a Phase 2 study, has not yet begun recruiting, sponsored by Medical University of South Carolina.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate the effects of oleoylethanolamide (OEA) supplementation on inflammation, the oral microbiome, neurocognitive function, and alcohol use in young adults ages 18 to 25 with alcohol use disorder (AUD). The main questions it aims to answer are: * Does OEA reduce peripheral markers of immune activation (IL-6, TNF-α, IL-1β, and LPS)? * Does OEA alter oral microbiome composition? * Does OEA improve neurocognitive measures of reward sensitivity and impulsivity? Researchers will compare OEA to a placebo (a look-alike substance with no active ingredient) to determine whether OEA improves biological and behavioral outcomes associated with AUD. Participants (N = 42) will: * Be randomly assigned to receive 300mg TRIPTI (providing 250 mg/day of OEA) or placebo for 6 weeks. * Provide blood, saliva, and urine samples * Complete cognitive testing and questionnaires * Report alcohol use during the study * Attend in-person study visits for monitoring and assessments This randomized, double-blind, placebo-controlled pilot trial will provide preliminary data on the potential efficacy of OEA as a multi-system intervention for young adults with AUD.
Interventions
- DRUG oleoylethanolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2031-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07503782
The ClinicalTrials.gov registry entry for NCT07503782 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which oleoylethanolamide is the first listed.
NCT07503782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07503782 about?
NCT07503782 is a clinical study titled "OEA for Young Adults With Alcohol Use Disorder". The goal of this clinical trial is to evaluate the effects of oleoylethanolamide (OEA) supplementation on inflammation, the oral microbiome, neurocognitive function, and alcohol use in young adults ages 18 to 25 with alcohol use disorder (AUD). The main questions it aims to answer are: * Does OEA r...
What is the current status of trial NCT07503782?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2026-08-01. Estimated completion is 2031-03-31.
What interventions are being tested in trial NCT07503782?
The interventions under investigation include: oleoylethanolamide (DRUG).
Who is sponsoring clinical trial NCT07503782?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.